Phosphatase

Other Names

Acid MonophosphataseAcid Nucleoside Diphosphate PhosphataseAcid PhosphataseAcid PhosphohydrolaseAcid Phosphomonoester HydrolaseAcid PhosphomonoesteraseACPACPaseAlkaline Phenyl PhosphataseAlkaline PhosphataseAlkaline PhosphohydrolaseAlkaline PhosphomonoesteraseALPAlpaseAPaseATPase (phosphomonoesterase context)GlycerophosphataseOrthophosphoric-monoester phosphohydrolase (acid optimum)Orthophosphoric-monoester phosphohydrolase (alkaline optimum)PhosphomonoesterasePhosphoprotein PhosphatasePhosphoric Monoester Hydrolase

Synopsis

Phosphatase: A Comprehensive Encyclopedic Reference

1. Identity and Classification

1.1 What Is Phosphatase?

Phosphatases are enzymes that catalyze the hydrolysis of phosphate esters. They are a large and diverse superfamily found across virtually all living organisms, and they play indispensable roles in cellular physiology. The term "phosphatase" does not describe a single molecule but rather a broad class of enzymes unified by one catalytic function: the removal of phosphate groups from substrates. When phosphatase is discussed in the context of dietary supplementation and natural health ingredients, the focus almost always falls on two principal sub-classes: alkaline phosphatase (ALP) and acid phosphatase (ACP), with particular scientific and clinical attention given to intestinal alkaline phosphatase (IAP) — the isoform most directly associated with gut health, supplementation studies, and potential therapeutic applications.

1.2 Nomenclature and Enzyme Classification

Alkaline phosphatase is a phospho-monoesterase that catalyzes hydrolysis of monoesters of phosphoric acid at alkaline pH, yielding phosphate salts and the corresponding alcohol. Its formal systematic name is orthophosphoric-monoester phosphohydrolase. The International Union of Biochemistry and Molecular Biology (IUBMB) assigns ALP the classification number EC 3.1.3.1 and acid phosphatase the classification number EC 3.1.3.2.

Alkaline phosphatases (ALPs) are a group of isoenzymes situated on the external layer of the cell membrane; they catalyze the hydrolysis of organic phosphate esters present in the extracellular space. Zinc and magnesium are significant co-factors for the biological activity of these enzymes. Although ALPs are available in various body tissues and have distinct physiochemical properties, they are true isoenzymes since they catalyze a similar reaction.

At its core, acid phosphatase functions as a hydrolase — an enzyme that catalyzes the cleavage of chemical bonds by adding water. Specifically, acid phosphatase facilitates the hydrolysis of phosphate esters to produce an alcohol and inorganic phosphate.

1.3 Human Isoforms

In humans, alkaline phosphatase exists in multiple isoforms encoded by distinct genes. Humans have four different genes encoding distinct alkaline phosphatase isoforms. In the liver, ALP is cytosolic and present in the canalicular membrane of the hepatocytes. ALPs are available in placenta, ileal mucosa, kidney, bone, and liver. However, most of the ALPs in serum (over 80%) are delivered from liver and bone and in more modest quantities from the intestines.

The isoform of greatest interest in supplementation science is tissue-nonspecific alkaline phosphatase (TNAP) — also written TNSALP — which is the primary isoform governing bone and dental mineralization, and intestinal alkaline phosphatase (IAP), which governs gut mucosal defense and microbiota homeostasis. Tissue-nonspecific alkaline phosphatase (TNAP) is a ubiquitously expressed enzyme that is best known for its role during mineralization processes in bones and skeleton. The enzyme metabolizes phosphate compounds like inorganic pyrophosphate and pyridoxal-5′-phosphate to provide, among others, inorganic phosphate for the mineralization and transportable vitamin B6 molecules.

Despite the fact that alkaline phosphatases are found in numerous tissues throughout the body, their exact physiological function remains largely unknown. This important qualification highlights that while certain functions of ALP are well-established (bone mineralization, LPS detoxification), the totality of ALP biology is still being characterized.

1.4 Natural Sources

Alkaline phosphatase is abundantly present in nature and is found in many tissues of the human body, including the liver, kidney, bone, and blood cells. ALP is a membrane-bound glycoprotein in which sialic acid is present as a sugar moiety. ALP is often found in milk and other fluids from a variety of organisms and animals.

Alkaline phosphatase is one of over 60 endogenous enzymes in raw bovine milk. The presence of a phosphatase activity in milk — first described as a phosphorus compound (Kay, 1925) — which was later identified as alkaline phosphatase, was first reported by Graham and Kay (1933). Bovine milk contains two principal indigenous phosphatases, namely alkaline and acid phosphatases, as well as other phosphatases such as ribonuclease.

The most commercially relevant natural source of phosphatase for supplement and pharmaceutical applications is the intestinal mucosa of calves (Bos taurus). Calf intestinal alkaline phosphatase (biAP or CIAP) has been purified from this tissue for decades and used in laboratory, preclinical, and clinical research. Human breast milk also contains phosphatase activity. Alkaline phosphatase is located on the luminal surface of the epithelial cells of the ducts and acinar glands of the mammary gland. The high levels of the enzyme in colostrum and intermediate milk may be due to the sudden activation of the milk secretory mechanism.

Beyond mammalian tissues, phosphatases are found in bacteria, fungi, and plants. Phytase, a specific type of phosphatase active against phytate (inositol hexaphosphate) in plant seeds, is derived from organisms including Aspergillus niger and specific Lactobacillus strains. Phytase is a phosphatase derived from Aspergillus niger.

1.5 Common Forms and Preparations

Phosphatase intended for supplementation or clinical use appears in several distinct forms:

Bovine intestinal alkaline phosphatase (biAP/CIAP): Purified from calf intestinal mucosa; used in Phase I and Phase II clinical trials as an intravenous infusion. This is the form with the most clinical human data for conditions such as sepsis-associated acute kidney injury (SA-AKI) and inflammatory bowel disease.
Recombinant human alkaline phosphatase (recAP / ilofotase alfa / efzimfotase alfa): Genetically engineered enzymes developed to replace biAP in clinical applications, combining characteristics of intestinal and placental ALP for increased stability and half-life. These are administered intravenously and are investigational drugs, not dietary supplements.
Asfotase alfa (STRENSIQ®): A bone-targeted recombinant human TNSALP enzyme replacement therapy, administered subcutaneously, approved for hypophosphatasia (HPP). A pharmaceutical drug, not a dietary supplement.
Oral IAP preparations: Bovine-derived IAP given orally in animal models and early human studies; investigational as a functional food component or medical food ingredient. Further research into the mechanisms of action and long-term health effects of IAP in maintaining overall intestinal health is essential for its future use as a dietary supplement or functional component in medical foods.
Raw milk phosphatase: Consumed passively as part of raw or minimally processed milk; inactivated by pasteurization. Because of its high heat resistance, ALP negative is used as an indicator of successful sterilization.
Phytase preparations: Enzyme supplements derived from fungal or bacterial fermentation, available as capsules or powders, used to improve mineral bioavailability from phytate-rich foods.

2. Historical and Traditional Use

2.1 Discovery and Early Scientific History

Phosphatase as a named biological entity was identified and characterized in the early twentieth century through laboratory biochemistry, rather than through traditional folk medicine. In 1923, Robert Robison, Ph.D., discovered a phosphatase abundant in the skeleton possibly to generate inorganic phosphate required to form bone mineral. In 1932, he postulated that an additional but unknown factor regulates skeletal mineralization. This factor would prove to be inorganic pyrophosphate, a potent inhibitor of mineralization and natural substrate for Robison's enzyme.

The recognition of phosphatase activity in milk followed shortly thereafter. The presence of a phosphatase activity in milk — first described as a phosphorus compound by Kay in 1925 — which was later identified as alkaline phosphatase, was first reported by Graham and Kay in 1933. From this point, alkaline phosphatase became one of the first enzymes to be exploited industrially, specifically as a quality-control marker for dairy pasteurization. Between 1924 and about 1970, nine more important indigenous enzymes were identified in milk and isolated and characterized. These were important as indicators of pasteurization of milk (alkaline phosphatase, γ-glutamyl transferase) or of mastitis (N-acetylglucosaminidase, acid phosphatase).

Formal characterization of ALP biochemistry in both bovine milk and calf intestinal mucosa proceeded through the 1950s, with systematic purification studies published in Biochemical Journal by R.K. Morton in 1953 and 1955, and studies on substrate specificity and inhibition conducted in the same era.

2.2 Traditional Use of Enzyme-Rich Foods

While phosphatase itself was not named or described in pre-modern medicine, the consumption of raw animal products rich in endogenous enzyme activity — including raw milk, fresh organ meats, and unprocessed fermented foods — has ancient and cross-cultural roots. Raw milk, consumed in many pastoral cultures across Eurasia, Africa, and the Americas before pasteurization, delivered native alkaline phosphatase activity into the gastrointestinal tract. Pasteurized milk loses its immune protection against allergy, a finding linked in part to the inactivation of ALP during heat treatment. Whether ancient cultures deliberately consumed raw milk to obtain enzyme activity was not described in historical records; however, the biological benefit of enzyme-rich colostrum to newborn mammals is an ancient and conserved phenomenon.

Fermented foods produced using microbial phosphatase-producing organisms — including traditional soy ferments, yogurt, fermented grain porridges, and kimchi — incidentally modified phytate content through phytase activity, improving mineral bioavailability. However, the explicit identification and intentional supplementation of phosphatase as a distinct ingredient is a modern development originating from 20th-century biochemistry.

3. Key Constituents and Mechanisms of Action

3.1 Structural and Biochemical Properties

Purified bovine ALP has a molecular mass of 187 kDa and an isoelectric point ranging from pH 5.4 to 6.0. It has maximal activity in the pH range 9.65 to 10.1 at 37°C. In its active form, the bovine ALP molecule forms complexes with zinc atoms that impart structural integrity and functional properties.

Three metal ions — two Zn²⁺ and one Mg²⁺ — are contained in the catalytic sites, and both types are crucial for enzymatic activity to occur. The enzymes catalyze the hydrolysis of monoesters in phosphoric acid, which can additionally catalyze a transphosphorylation reaction with large concentrations of phosphate acceptors.

Acid phosphatase, by contrast, functions optimally at acidic pH values (approximately pH 4–6) and is localized predominantly in lysosomes. One of its prominent sites of action is the lysosome, an organelle often dubbed the "recycling center" of the cell. Lysosomes contain a cocktail of enzymes, including lysosomal acid phosphatase, that breaks down waste materials, damaged cellular components, and external particles taken up by the cell. Acid phosphatase aids in the hydrolysis of phosphoric esters and anhydrides within lysosomes. This process is paramount for recycling cellular components, ensuring that valuable molecules are reclaimed and waste is efficiently expelled or reused.

3.2 Principal Mechanisms of Action

3.2.1 Bone and Dental Mineralization

The best-established physiological function of TNAP/ALP is the regulation of skeletal mineralization. Hypophosphatasia (HPP) results from ALPL mutations leading to deficient activity of the tissue-non-specific alkaline phosphatase isozyme (TNAP) and thereby extracellular accumulation of inorganic pyrophosphate (PPi), a natural substrate of TNAP and potent inhibitor of mineralization. TNAP hydrolyzes inorganic pyrophosphate (PPi) to allow skeletal and dental mineralization. Conversely, elevated extracellular PPi levels inhibit bone mineralization and cause impaired skeletal mineralization.

3.2.2 Vitamin B6 Metabolism

A second well-characterized substrate of TNAP is pyridoxal-5′-phosphate (PLP), the active form of vitamin B6. TNAP hydrolyzes pyridoxal phosphate to allow cellular pyridoxal uptake and stimulate vitamin B6-dependent reactions. Vitamin B6 is metabolized by alkaline phosphatase (ALP). In hypophosphatasia, with very limited ALP activity, vitamin B6 cannot be broken down to the molecules that can cross from the blood into the brain, so infants with B6-dependent HPP-related seizures are prescribed vitamin B6.

3.2.3 LPS Detoxification and Endotoxemia

One of the most extensively studied mechanisms in the context of IAP supplementation is the dephosphorylation and detoxification of lipopolysaccharide (LPS), the major component of the outer membrane of Gram-negative bacteria and a potent driver of systemic inflammation. Intestinal alkaline phosphatase (IAP) is a brush border enzyme critical for maintaining gut homeostasis by detoxifying bacterial endotoxins, regulating nutrient metabolism, and modulating immune responses. It strengthens intestinal barrier function by upregulating tight junction proteins and mitigating inflammation via lipopolysaccharide (LPS) detoxification and immunomodulatory pathways.

IAP is an anti-inflammatory factor that detoxifies a variety of bacterially derived proinflammatory factors such as LPS, CpG-DNA, and flagellin.

3.2.4 Gut Barrier Integrity and Tight Junction Upregulation

IAP plays a multifunctional role in diverse biological processes, including gut health maintenance and function. Research has summarized the protective effects of IAP on intestinal barrier integrity, encompassing the physical, chemical, microbial, and immune barriers. IAP promotes gut barrier function, likely through the upregulation of intestinal tight junction proteins.

3.2.5 Gut Microbiota Homeostasis

Mice deficient in the brush-border enzyme intestinal alkaline phosphatase (IAP) suffer from dysbiosis, and oral IAP supplementation normalizes the gut flora. The mechanism involves IAP's dephosphorylation of luminal nucleotide triphosphates (NTPs), which would otherwise inhibit commensal bacterial growth. IAP-knockout mice had dramatically fewer and also different types of aerobic and anaerobic microbes in their stools compared with wild-type mice. Oral supplementation of IAP favoured the growth of commensal bacteria, enhanced restoration of gut microbiota lost due to antibiotic treatment, and inhibited the growth of a pathogenic bacterium (Salmonella typhimurium). IAP is involved in the maintenance of normal gut microbial homeostasis and may have therapeutic potential against dysbiosis and pathogenic infections.

3.2.6 ATP-to-Adenosine Conversion and Renal Protection

Beyond LPS detoxification, ALP can dephosphorylate extracellular ATP to adenosine — a molecule with potent anti-inflammatory and tissue-protective properties. IAP may also play an important part in host defense by dephosphorylating extracellular ATP to adenosine. Adenosine exerts potent anti-inflammatory and renal tissue protective effects. This mechanism is a key proposed basis for ALP's renal protective effects in sepsis.

3.2.7 Non-Shivering Thermogenesis

TNAP has been identified as a key enzyme in non-shivering adaptive thermogenesis, by dephosphorylating phosphocreatine in the mitochondrial creatine futile cycle. This function, while biochemically established, has not yet translated into supplementation applications for humans.

4. Scientific Evidence by Area of Use

4.1 Hypophosphatasia (HPP) and Bone Mineralization

Background: Hypophosphatasia (HPP) is a rare disease caused by loss-of-function mutations in the tissue-nonspecific alkaline phosphatase (TNAP) gene. HPP causes a multisystemic syndrome with a predominant bone phenotype. The clinical spectrum ranges from high lethality in early onset (<6 months) HPP to mild late-onset syndromes.

Hypophosphatasia (HPP) is a rare, inherited metabolic bone disorder characterized by low serum alkaline phosphatase (ALP) activity and impaired bone mineralization. HPP is caused by loss-of-function mutations within the gene that encodes tissue-nonspecific alkaline phosphatase (TNSALP). Extracellular accumulation of TNSALP natural substrates occurs, leading to inhibited mineralization of both teeth and bone.

Clinical Evidence (Asfotase Alfa): The most rigorously studied phosphatase therapeutic intervention in humans is enzyme replacement therapy (ERT) for HPP. Subcutaneous asfotase alfa, a first-in-class bone-targeted human TNAP enzyme replacement therapy, is the first compound approved for long-term treatment of bone manifestations in pediatric-onset HPP. In noncomparative clinical trials (treatment up to 7 years), this treatment was associated with skeletal, respiratory, and functional improvement in perinatal, infantile, and childhood-onset HPP. Compared with age-matched historical controls, patients with life-threatening perinatal and infantile HPP treated with asfotase alfa had substantially improved bone mineralization, survival, and ventilation-free survival.

Asfotase alfa is a recombinant human alkaline phosphatase used as treatment for the underlying cause of HPP. It enhances survival in life-threatening HPP and improves bone mineralization, muscle strength, and pulmonary function. However, discontinuation of asfotase alfa leads to reappearance of bone hypomineralization.

A second-generation therapy, efzimfotase alfa (ALXN1850), has entered Phase 1 clinical trials. A first-in-human, open-label, dose-escalating Phase 1 trial evaluated efzimfotase alfa safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity. Fifteen adults (five per cohort) with HPP received efzimfotase alfa in doses of 15 mg (cohort 1), 45 mg (cohort 2), or 90 mg (cohort 3) as one intravenous dose followed by three weekly subcutaneous doses. Treatment-emergent adverse events occurred in 12 (80%) of participants. Eight (53%) of participants had injection site reactions observed after 10 of 41 (24%) subcutaneous injections. Most injection site reaction adverse events were mild and resolved within 1–2 days.

Evidence Strength: Evidence for ALP enzyme replacement therapy in HPP is strong within the disease-specific context: non-randomized but historically controlled trials for asfotase alfa demonstrate meaningful clinical benefit. These are pharmaceutical therapies requiring a diagnosis and prescription, not over-the-counter supplements.

4.2 Sepsis-Associated Acute Kidney Injury (SA-AKI)

Background: Acute kidney injury (AKI) occurs in 55–60% of critically ill patients, and sepsis is the most common underlying cause. No pharmacological treatment options are licensed to treat sepsis-associated AKI (SA-AKI); only supportive renal replacement therapy (RRT) is available. One of the limited number of candidate compounds in clinical development to treat SA-AKI is alkaline phosphatase (AP).

Phase I/II Human Data (Bovine IAP): Bovine intestinal AP (biAP) was administered to 67 healthy volunteers in various doses to determine safety and pharmacokinetics. A proportional and linear response to the different loading doses was found. Continuous infusion of biAP for 24–72 hours showed a stable level throughout the period of infusion and was used to determine the elimination half-life of approximately 8 hours. Following the efficacy studies in animals and the safety and kinetics studies in healthy volunteers, a small Phase 2 clinical trial in 36 suspected or proven Gram-negative sepsis patients (with or without AKI) was conducted. Patients received a loading dose of 67.5 U/kg biAP and a continuous infusion of 132.5 U/kg/24 h biAP for 24 hours. No safety concerns emerged in this critically ill population.

Based on these and other animal studies, Phase 1 and 2 clinical trials using IAP in septic patients to prevent AKI were conducted using an intravenous formulation of bovine-derived IAP. Systemic IAP was well tolerated and had little to no observed toxicity or side effects. Septic patients who received IAP had significant improvement in kidney function, as demonstrated by decreases in median plasma creatinine levels and creatinine clearance.

Pivotal Phase IIa/IIb Trial (recAP/Ilofotase Alfa): Given the limitations of bovine-derived ALP, a human recombinant AP (ilofotase alfa) was developed. In the development of the human recombinant form of AP (recAP), it was decided to combine the biologically active intestinal AP and the very stable placental AP. The resultant biologically active and long half-life recAP was produced for the upcoming large Phase 2 clinical trial. A Phase 2a/2b Proof-of-Concept and Dose-Finding trial (STOP-AKI) with ilofotase alfa in 301 patients with sepsis-associated AKI has been completed.

A Phase I trial of recAP in healthy volunteers used the following protocol: In a randomized, double-blind, placebo-controlled Phase 1 trial, healthy volunteers received a single dose of recAP (200, 500, 1,000 or 2,000 U/kg; n = 33; 3:1 ratio) or multiple doses of recAP (500 or 1,000 U/kg; n = 18; 2:1 ratio) via a 1-hour intravenous infusion on three consecutive days.

Evidence Strength: Evidence for ALP in SA-AKI is preliminary-to-moderate: Phase 1 and small Phase 2 trials show signals of renal benefit and acceptable safety, but the interventions under investigation are intravenous pharmaceutical-grade products administered in intensive care settings, not consumer dietary supplements. Results from the STOP-AKI Phase IIa/IIb trial are relevant to drug development, not over-the-counter supplementation.

4.3 Gut Health, Intestinal Barrier Function, and Inflammatory Bowel Disease (IBD)

Emerging evidence highlights IAP's pleiotropic roles in intestinal barrier protection, microbiota regulation, and inflammation modulation, positioning IAP as a potential therapeutic target for gastrointestinal and systemic disorders, including inflammatory bowel disease (IBD), necrotizing enterocolitis (NEC), and metabolic syndrome.

While IAP deficiency is linked to varying degrees of physiological dysfunctions across multiple organ systems, supplementation of IAP has been proven to be beneficial in several translational and clinical studies. Numerous studies reporting on the different roles and the potential therapeutic value of IAP across species have been published during the last decade.

A clinical trial program examined oral bovine IAP in patients with moderate-to-severe ulcerative colitis. It is conceivable that a reduction in the amount of active LPS in the intestinal lumen by exogenously administered AP will result in a corresponding relative decrease of LPS influx in the circulation and, as a consequence, inhibit the LPS-mediated systemic inflammatory response. Dephosphorylated LPS will reduce the ability of LPS to activate TLR-4, resulting in decreased nuclear factor κB activation and a decreased local inflammatory response. The safety, tolerability, and pharmacokinetics of exogenously administered BIAP for human use have previously been studied in animal toxicology studies and in Phase I and IIa clinical trials.

IAP activity is modulated by dietary components such as carbohydrates, fats, probiotics, and vitamins, and has a dose-dependent effect.

Evidence Strength for IBD: Preclinical evidence (cell culture and rodent models) is consistent and mechanistically plausible. Clinical human trial data for oral IAP in IBD is limited; the available evidence consists of small early-phase trials and remains insufficient to draw conclusions about efficacy. This area is under active investigation.

4.4 Metabolic Syndrome and Type 2 Diabetes

Animal and observational human data suggest a relationship between IAP activity and metabolic health. The role of IAP in diabetes and metabolic syndrome has been examined in human and translational studies. A case-control study in metabolic disease indicated that type 2 diabetes mellitus (T2DM) patients have approximately 50% less fecal IAP compared to healthy controls. High IAP can protect against diabetes irrespective of obesity, whereas healthy controls with low IAP levels also appeared to be vulnerable to the development of metabolic syndrome.

Both endogenous and orally supplemented IAP inhibit absorption of endotoxin (lipopolysaccharides) that occurs with dietary fat, and oral IAP supplementation prevents as well as reverses metabolic syndrome in mice. Furthermore, IAP supplementation improves the lipid profile in mice fed a standard, low-fat chow diet. These results point to a potentially unique therapy against metabolic syndrome in at-risk humans.

It was shown that IAP knockout mice display features of metabolic syndrome such as obesity, elevated blood glucose, endotoxemia, glucose intolerance, and hyperinsulinemia. Supplementation with oral IAP was able to prevent and reverse these conditions in both the KO mice as well as in models of high-fat-diet-induced metabolic syndrome.

IAP deficiency leads to metabolic endotoxemia, which precipitates low-grade systemic inflammation, and the resulting increased levels of proinflammatory cytokines TNF-α and IL-1β inhibit IRS proteins, leading to insulin resistance, hypoinsulinemia, hyperglycemia, and T2DM.

Evidence Strength: Mechanistic evidence from mouse models is robust and internally consistent. Human data are currently observational (case-control), providing associations rather than causation. No adequately powered randomized controlled trials in humans have been completed examining oral IAP supplementation for metabolic syndrome outcomes. This area remains investigational.

4.5 Gut Microbiota Modulation and Dysbiosis Prevention

IAP's role in shaping the composition of the gut microbiome has been documented in both animal and some human-relevant observational work. IAP-knockout mice had dramatically fewer and also different types of aerobic and anaerobic microbes in their stools compared with wild-type mice. Oral supplementation of IAP favoured the growth of commensal bacteria, enhanced restoration of gut microbiota lost due to antibiotic treatment, and inhibited the growth of a pathogenic bacterium (Salmonella typhimurium).

Co-administration of IAP with azithromycin early in life prevents mice from susceptibility to the later development of metabolic syndrome. This effect is associated with alterations in the composition of the gut microbiota. IAP may represent a novel treatment against metabolic syndrome in humans.

Evidence Strength: Evidence is animal-model based (primarily rodent). No human RCTs examining the effect of oral IAP supplementation on gut microbiota composition have been reported in the peer-reviewed literature. Evidence is preliminary.

4.6 Necrotizing Enterocolitis (NEC) and Neonatal Gut Health

For infants with low immunity, ALP intake is a good prebiotic for protecting the infant's intestine from potential pathogenic bacteria. Research on IAP in necrotizing enterocolitis — a severe inflammatory condition of the newborn intestine — has been an active area. Evidence positions IAP as a potential therapeutic target for necrotizing enterocolitis (NEC). Gut barrier dysfunction and gut-derived chronic inflammation play crucial roles in human aging. The gut brush border enzyme intestinal alkaline phosphatase (IAP) functions to inhibit inflammatory mediators and also appears to be an important positive regulator of gut barrier function and microbial homeostasis.

Evidence Strength: NEC-focused IAP research is primarily in animal models and mechanistic studies. Human clinical trial data are limited.

4.7 Mineral Bioavailability (Phytase as a Phosphatase Subtype)

Phytase — a phosphatase that cleaves phosphate from phytic acid (phytate) in plant seeds — has a distinct and comparatively well-studied role in human nutrition. Phytate is an anti-nutritional factor that chelates divalent minerals (zinc, iron, calcium), reducing their intestinal absorption. Supplemental phytase, administered orally, can degrade phytate in the gut lumen, liberating bound minerals. Brnic et al. examined the effect of phytase on zinc absorption from a millet-based porridge fed to young Burkinabe children. (Eur J Clin Nutr, 2017; 71(1):137–141). This represents one of the more directly clinically tested applications of supplemental phosphatase-class enzymes in human populations, particularly in regions where phytate-rich staples form the dietary basis.

Evidence Strength: Moderate evidence exists that phytase supplementation can improve zinc and iron bioavailability in populations consuming high-phytate diets, based on multiple human intervention trials. This is the most directly consumer-relevant application of a phosphatase enzyme as a dietary supplement.

5. Body Systems and Health Areas Associated with Phosphatase

5.1 Skeletal and Dental System

Phosphatases play critical roles in diverse biological processes such as extracellular nucleotide homeostasis, transport of molecules across membranes, intracellular signaling pathways, and vertebrate mineralization. The dependence of bone and enamel mineralization on ALP activity is among the most clinically validated functions of the enzyme family. Loss-of-function mutations in the ALPL gene result in HPP, with its hallmark clinical manifestations of rickets, osteomalacia, dental hypomineralization, and fractures.

5.2 Gastrointestinal System

IAP is an endogenous protein expressed by the intestinal epithelium that is believed to play a vital role in maintaining gut homeostasis. Intestinal alkaline phosphatase (IAP) is a membrane-bound glycoprotein that is exclusively expressed in villus-associated enterocytes of proximal small intestine and hence recognized as an enterocyte differentiation marker.

5.3 Renal System

The renal protective effect of purified bovine intestinal AP has been demonstrated in critically ill sepsis patients. The proposed mechanism involves ALP's dephosphorylation of ATP to adenosine, which is renoprotective, and the detoxification of circulating LPS that would otherwise activate inflammatory cascades causing tubular injury.

5.4 Immune System

IAP strengthens intestinal barrier function by upregulating tight junction proteins and mitigating inflammation via lipopolysaccharide (LPS) detoxification and immunomodulatory pathways.

5.5 Metabolic / Endocrine System

Western diets promote a higher intestinal translocation of pro-inflammatory microbial components like lipopolysaccharide into the systemic circulation, thus leading to chronic low-grade systemic inflammation and metabolic shifts towards higher body fat accumulation that ultimately result in metabolic syndrome and diabetes. Many data indicate that intestinal alkaline phosphatase (IAP) consistently reduces inflammation in animal models and in diseases such as ulcerative colitis, peritonitis, sepsis, and heart surgery in humans.

5.6 Nervous System

Patients with inherited loss-of-function mutations in the ALPL gene and consequently altered TNAP activity suffer from the rare metabolic disease hypophosphatasia (HPP). This systemic disease is mainly characterized by impaired bone and dental mineralization but may also be accompanied by neurological symptoms, including anxiety disorders, seizures, and depression. The neurological manifestations of HPP arise from TNAP's role in pyridoxal-5′-phosphate metabolism, linking ALP activity directly to neurotransmitter synthesis pathways dependent on vitamin B6.

6. Dosage Forms and Doses Reported in Studies

The following dosages are reported strictly as described in the cited clinical and preclinical research literature. None represent established recommended consumer supplement doses, as no regulatory body has established such guidelines for phosphatase supplementation in the general population.

Bovine IAP — intravenous (sepsis/AKI clinical trials): Treatment in one prospective randomized controlled trial consisted of an intravenous bolus injection of AP (calf intestinal AP) at 67.5 U/kg bodyweight over 10 minutes, followed by continuous infusion of 132.5 U/kg/24 hours.
Recombinant human ALP (recAP/ilofotase alfa) — intravenous (Phase I, healthy volunteers): Healthy volunteers received a single dose of recAP at 200, 500, 1,000, or 2,000 U/kg or multiple doses of recAP at 500 or 1,000 U/kg via a 1-hour intravenous infusion on three consecutive days.
Recombinant ALP — dosing rationale for patient studies: The dosing rationale for the patient studies was primarily based on Cmin values and exposure shown to be associated with objective clinical benefit in SA-AKI patients treated with biAP in previous clinical studies, indicating that clinical benefit occurred above serum recAP concentrations of 290 U/L (170 ng/mL).
Asfotase alfa — subcutaneous (pediatric HPP): One infant with HPP began enzyme replacement therapy using asfotase alfa at the standard dose of 6 mg/kg/week.
Efzimfotase alfa — intravenous/subcutaneous (Phase I, adult HPP): Fifteen adults with HPP received efzimfotase alfa in doses of 15 mg (cohort 1), 45 mg (cohort 2), or 90 mg (cohort 3) as one intravenous dose followed by three weekly subcutaneous doses.
Oral IAP (animal models): Animal studies examining metabolic syndrome used oral IAP supplementation administered alongside high-fat diet, though specific dose amounts in mass-per-kilogram were not extractable from the available abstracts and must be obtained from the primary publications.

No standardized oral dosage form of phosphatase for human dietary supplement use has been approved or established by any regulatory body (including the NIH Office of Dietary Supplements, FDA, EFSA, or EMA) as of the time of writing.

7. Safety Considerations and Notable Interactions

7.1 Safety of Intravenous Alkaline Phosphatase in Clinical Trials

A total of 51 male and female healthy volunteers were included in the Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) trial, of which 37 subjects were exposed to single doses of up to 2,000 U/kg recAP or daily recAP doses of 500 or 1,000 U/kg administered for three consecutive days. No serious adverse events (SAEs) were observed, and there were no clinically significant findings from clinical laboratory, 12-lead electrocardiogram, continuous cardiac monitoring, or physical examination during the trial. All treatment-emergent adverse events (TEAEs) were transient and had resolved without sequelae by the follow-up period.

None of the subjects were positive for anti-drug antibodies (ADAs). The overall percentage of subjects reporting TEAEs was generally comparable in the placebo and recAP groups. Furthermore, the number of TEAEs did not increase with increasing dose.

Systemic IAP was well tolerated and had little to no observed toxicity or side effects in clinical trials involving septic patients receiving bovine IAP intravenously.

7.2 Injection Site Reactions with Subcutaneous Administration

Treatment-emergent adverse events occurred in 12 (80%) of participants in the efzimfotase alfa Phase 1 trial. Eight (53%) of participants had injection site reactions observed after 10 of 41 (24%) subcutaneous injections. Most injection site reaction adverse events were mild and resolved within 1–2 days.

7.3 Immunogenicity Considerations for Bovine-Derived Sources

Given that biAP is retrieved from calf intestine, it has various drawbacks, including the (minimal) risk of bovine spongiform encephalopathy and occurrence of an undesirable immune response. This concern motivated the development of recombinant human ALP formulations, which do not carry the theoretical BSE risk and are less likely to elicit anti-drug antibodies.

Oral administration or injection of ALP will not cause harm to the body and has a variety of probiotic effects, according to a review published in a peer-reviewed Chinese Academy of Sciences journal, though this is a broad characterization and should be interpreted in the context of the specific preparation and population studied.

7.4 ALP as a Diagnostic Marker: Implications for Laboratory Interpretation

The clinical relevance of acid phosphatase is particularly evident in diagnostics. Its levels can act as indicators for certain medical conditions. The correlation between increased acid phosphatase levels and bone disease underscores its diagnostic relevance. ALP is defined as a group of enzymes that remove phosphate groups from molecules, functioning optimally in alkaline conditions with a pH of 9–10, and are predominantly found in the liver and bone. ALP levels can vary due to factors such as digestion, cholestasis, injury, fasting, and certain medical conditions.

Because serum ALP is a widely used clinical biomarker for liver and bone disease, any intervention — dietary, supplemental, or pharmaceutical — that modifies ALP levels may confound diagnostic interpretation in patients undergoing evaluation for these conditions.

7.5 Occupational Sensitization (Phytase)

Workers exposed to aerosolized phytase in food or feed production settings have been reported to develop IgE-mediated sensitization. Doekes et al. reported occupational IgE sensitisation to phytase, a phosphatase derived from Aspergillus niger, published in Occupational and Environmental Medicine, 1999; 56(7):454–9. This risk pertains primarily to industrial or occupational inhalation exposure, not to oral supplementation by consumers.

7.6 Interaction with Vitamin B6 Status in HPP

It may seem counterintuitive, but not only is it unnecessary to restrict dietary intake of vitamin B6 in HPP, but it is also used to treat the seizures that occur in perinatal HPP. Vitamin B6 is metabolized by alkaline phosphatase (ALP). A vitamin B6 overdose can cause significant symptoms. This interaction is clinically relevant for HPP patients on enzyme replacement therapy, where TNAP activity is being pharmacologically restored: as ALP activity normalizes, vitamin B6 metabolism normalizes, and previously supplemented patients may need to be monitored for altered B6 status.

7.7 Heat Sensitivity and Oral Bioavailability

Phosphatase enzymes are proteins and subject to denaturation by heat, acid, and proteolysis. Because of its high heat resistance compared with many enzymes, ALP-negative status is used as an indicator of successful milk sterilization — though ALP is nonetheless substantially inactivated by standard pasteurization conditions. When consumed orally, ALP faces gastric acid and pancreatic proteases. The survivability and biological activity of orally ingested ALP in the human gastrointestinal tract is a key challenge noted in the supplementation literature, motivating research into innovative delivery systems. Innovative delivery systems such as liposomes, hydrogels, and exosomes are being explored to enhance IAP stability and bioavailability.

7.8 Bisphosphonate Interactions in Bone Disease

In patients with HPP — where ALP activity is deficient — the use of bisphosphonates (bone-resorption inhibitors commonly prescribed for osteoporosis) is specifically contraindicated. Case reports and management discussions caution against bisphosphonate use in the setting of hypophosphatasia. This interaction, while specific to HPP management, illustrates that altering the phosphatase-mediated regulation of bone mineral metabolism can have serious implications for concurrent pharmacological treatment choices.

Summary of Evidence Quality

The scientific literature on phosphatase as a supplement or therapeutic agent spans a wide spectrum of evidence quality:

Strong/established: The role of ALP in bone mineralization; the pharmacology of asfotase alfa as ERT for pediatric HPP; ALP as a pasteurization marker in dairy.
Moderate/promising: Renal protective effects of intravenous bovine IAP in septic patients (Phase 1–2 data); phytase for mineral bioavailability in high-phytate diets.
Preliminary/investigational: Oral IAP for gut barrier integrity and IBD (animal + small human data); IAP and metabolic syndrome (rodent models + case-control human studies); IAP for microbiota modulation (rodent data).
Insufficient human evidence: Oral phosphatase supplementation for any indication in the general healthy population; optimal dosing for oral IAP in humans; long-term safety of chronic oral phosphatase use.

References

Health Conditions

Health conditions that Phosphatase may help support.

No conditions available.

Body Systems

Body systems that Phosphatase may help support.

No body systems available.